---
health_md_version: "1.0"
record_id: "anonymous-001"
generated: "2024-02-17T10:00:00Z"
privacy_level: "anonymous"
last_updated: "2024-02-17T10:00:00Z"
data_sources: ["ehr_export", "manual_entry"]
---

# Health Record - Anonymous Patient 001

## Demographics
- **Age Range:** 30-39
- **Sex:** Female
- **Gender Identity:** Female
- **Occupation Category:** Technology
- **Location Region:** Northern Europe
- **Languages:** Swedish, English

## Current Medications

### Metformin 500mg
- **Generic Name:** Metformin Hydrochloride
- **Indication:** Type 2 Diabetes Mellitus (ICD-10: E11.9)
- **Dosage:** 500mg twice daily with meals
- **Route:** Oral
- **Started:** January 2024
- **Duration:** 1 month
- **Prescriber:** Endocrinologist
- **Side Effects:** None reported
- **Adherence:** Excellent (>90%)
- **Clinical Notes:** Well tolerated, no gastrointestinal issues reported

### Lisinopril 10mg
- **Generic Name:** Lisinopril
- **Indication:** Hypertension (ICD-10: I10)
- **Dosage:** 10mg once daily, morning
- **Route:** Oral
- **Started:** August 2023
- **Duration:** 6 months
- **Prescriber:** Family Medicine Provider
- **Clinical Notes:** Good blood pressure control, monitoring electrolytes

## Medical History

### Type 2 Diabetes Mellitus (January 2024)
- **ICD-10:** E11.9 - Type 2 diabetes mellitus without complications
- **Onset:** January 2024 (newly diagnosed)
- **Presentation:** Classic symptoms - polyuria, polydipsia, fatigue
- **Diagnostic Criteria Met:**
  - HbA1c: 8.2% (>6.5% diagnostic threshold)  
  - Fasting plasma glucose: 180 mg/dL (>126 mg/dL diagnostic)
- **Risk Factors:**
  - Family history of diabetes (parent)
  - Overweight (BMI 31-32 range)
  - Sedentary lifestyle
  - Previous gestational diabetes
- **Current Status:** Good glycemic control achieved with metformin
- **Complications:** None identified to date

### Hypertension (August 2023)  
- **ICD-10:** I10 - Essential hypertension
- **Onset:** August 2023
- **Discovery:** Routine screening visit
- **Initial Readings:** Consistently >140/90 mmHg
- **Peak Reading:** 158/96 mmHg
- **Current Status:** Well controlled with ACE inhibitor
- **Target:** <130/80 mmHg (achieved)

### Pregnancy History
- **Gestational Diabetes:** 2019 (resolved postpartum)
- **Delivery:** Full-term, uncomplicated
- **Postpartum:** Blood sugars normalized, annual screening recommended

## Lab Results

### Hemoglobin A1C Trend
- **February 2024:** 6.8% ✓ (Target: <7.0%)
- **January 2024:** 7.4% (1 month post-treatment)
- **January 2024:** 8.2% (Initial diagnosis)
- **Reference Range:** <5.7% (normal), 5.7-6.4% (prediabetes), >6.5% (diabetes)
- **Clinical Significance:** Excellent response to metformin therapy
- **Trend:** Rapidly improving (↓ 1.4% in 4 weeks)

### Basic Metabolic Panel (February 2024)
- **Glucose (fasting):** 118 mg/dL (Ref: 70-100) - Improved from 180
- **Creatinine:** 0.8 mg/dL (Ref: 0.6-1.2) - Normal kidney function
- **eGFR:** >60 mL/min/1.73m² - Normal
- **Sodium:** 140 mEq/L (Ref: 136-145)
- **Potassium:** 4.1 mEq/L (Ref: 3.5-5.0) - Normal on ACE inhibitor
- **Chloride:** 102 mEq/L (Ref: 98-107)
- **BUN:** 15 mg/dL (Ref: 7-20)

### Lipid Panel (January 2024)
- **Total Cholesterol:** 198 mg/dL (Ref: <200) - Acceptable
- **LDL Cholesterol:** 128 mg/dL (Ref: <100) - Elevated
- **HDL Cholesterol:** 42 mg/dL (Ref: >50 for women) - Low
- **Triglycerides:** 156 mg/dL (Ref: <150) - Slightly elevated
- **Non-HDL Cholesterol:** 156 mg/dL (Ref: <130) - Elevated
- **Clinical Plan:** Lifestyle modifications, recheck in 3 months

### Thyroid Function (January 2024)
- **TSH:** 2.8 mIU/L (Ref: 0.4-4.0) - Normal
- **Clinical Notes:** Checked due to fatigue symptoms, normal function

## Vital Signs

### Blood Pressure Trend
- **February 2024:** 126/78 mmHg (Well controlled) ✓
- **January 2024:** 132/82 mmHg (Improved)
- **December 2023:** 145/88 mmHg (On treatment)
- **August 2023:** 158/96 mmHg (Pre-treatment)
- **Target:** <130/80 mmHg (Achieved)

### Anthropometrics  
- **Current Weight:** 78 kg (↓ from 85 kg baseline)
- **Height:** 165 cm
- **Current BMI:** 28.7 (↓ from 31.2) - Overweight category
- **BMI Goal:** <25 (Normal weight)
- **Waist Circumference:** 92 cm (↓ from 98 cm)
- **Weight Loss:** 7 kg in 4 months (sustainable pace)

## Allergies & Intolerances

### Drug Allergies
- **Penicillin:** Documented severe reaction (anaphylaxis, 2015)
  - **Reaction:** Throat swelling, hives, hypotension
  - **Emergency Treatment:** Epinephrine, IV steroids
  - **Allergy Bracelet:** Worn consistently

### Food Sensitivities  
- **Lactose Intolerance:** Moderate
  - **Symptoms:** Bloating, diarrhea if >1 cup milk
  - **Management:** Lactase supplements, lactose-free products

## Clinical Timeline

### February 2024: Diabetes Follow-up Visit
- **Provider Type:** Endocrinologist
- **Visit Type:** Follow-up appointment
- **Chief Complaint:** Routine diabetes management
- **Interval History:** 
  - Excellent medication adherence
  - 7 kg weight loss through diet changes
  - Increased physical activity (walking 30 min daily)
  - No hypoglycemic episodes
- **Physical Exam:** 
  - BP: 126/78 mmHg (improved)
  - Weight: 78 kg (7 kg weight loss)
  - Feet: No ulcers, good pulses, normal sensation
- **Assessment:** 
  - Type 2 diabetes with excellent glycemic control
  - Hypertension well controlled
  - Successful weight loss
- **Plan:**
  - Continue metformin 500mg BID
  - Continue lisinopril 10mg daily  
  - Nutrition counseling referral
  - HbA1c recheck in 3 months
  - Annual diabetic eye exam scheduled
  - Continue current exercise regimen

### January 2024: Initial Diabetes Diagnosis
- **Provider Type:** Family Medicine
- **Visit Type:** Follow-up for abnormal screening labs
- **Chief Complaint:** Fatigue, increased thirst, frequent urination
- **History of Present Illness:**
  - 3-month history of progressive fatigue
  - Increased thirst and urination for 6 weeks
  - Unintentional weight loss (3 kg)
  - No blurred vision or infections
- **Labs Review:**
  - HbA1c: 8.2% (clearly diabetic)
  - Fasting glucose: 180 mg/dL (clearly diabetic)
  - Basic metabolic panel: Normal kidney function
- **Assessment:** Type 2 Diabetes Mellitus, newly diagnosed
- **Plan:**
  - Start metformin 500mg BID with meals
  - Diabetes education class enrollment
  - Endocrinology referral
  - Lifestyle counseling (diet and exercise)
  - Home glucose monitoring temporarily
  - Follow-up in 4 weeks

### August 2023: Hypertension Diagnosis  
- **Provider Type:** Family Medicine  
- **Visit Type:** Annual preventive care
- **Finding:** Elevated blood pressure on routine screening
- **Confirmatory Readings:** 
  - Visit 1: 158/96, 152/94, 155/95 mmHg
  - Visit 2 (1 week later): 148/90, 145/88 mmHg
  - Home monitoring: Average 150/92 mmHg
- **Assessment:** Stage 2 hypertension
- **Plan:**
  - Start lisinopril 10mg daily
  - Lifestyle modifications (diet, exercise, weight loss)
  - Home blood pressure monitoring
  - Follow-up in 4 weeks

## Care Team

### Primary Care
- **Provider Type:** Family Medicine Physician
- **Practice Setting:** Community Health Center
- **Relationship Duration:** 4 years (2020-present)
- **Role:** Primary care coordination, preventive care

### Specialty Care
- **Provider Type:** Endocrinologist  
- **Practice Setting:** University Hospital Diabetes Center
- **Relationship Duration:** 2 months (2024-present)
- **Role:** Diabetes management and education

### Allied Health
- **Diabetes Educator:** Registered Nurse, CDE
- **Dietitian:** Registered Dietitian Nutritionist
- **Pharmacist:** Clinical pharmacist for medication management

## Health Maintenance

### Preventive Care Schedule
- **HbA1c:** Every 3 months (due May 2024)
- **Lipid Panel:** Every 6 months (due July 2024)
- **Kidney Function:** Every 6 months (due August 2024)
- **Diabetic Eye Exam:** Annually (due January 2025)
- **Diabetic Foot Exam:** Every visit
- **Blood Pressure:** Home monitoring 2x/week

### Immunizations
- **COVID-19:** Up to date (last booster October 2023)
- **Influenza:** Annual (received September 2023)
- **Tdap:** Up to date (2021)

## Goals and Metrics

### Diabetes Management Goals
- **HbA1c:** <7.0% ✓ (Current: 6.8%)
- **Fasting Glucose:** 70-130 mg/dL (Current: ~118 mg/dL) ✓
- **Weight Loss:** 5-10% body weight (Current: 8.2% lost) ✓

### Cardiovascular Risk Goals
- **Blood Pressure:** <130/80 mmHg ✓ (Current: 126/78)
- **LDL Cholesterol:** <100 mg/dL (Current: 128 mg/dL - needs work)
- **HDL Cholesterol:** >50 mg/dL (Current: 42 mg/dL - needs work)

### Lifestyle Goals  
- **Physical Activity:** 150 min/week moderate exercise ✓
- **Weight:** BMI <25 (Current: 28.7 - in progress)
- **Diet:** Mediterranean-style, low glycemic index ✓

## Notes and Observations

### Patient Engagement
- **Health Literacy:** High - understands condition well
- **Technology Use:** Comfortable with apps and monitoring
- **Support System:** Strong family support for lifestyle changes
- **Barriers:** Work schedule limits exercise opportunities

### Clinical Pearls
- **Rapid Response:** Excellent HbA1c improvement (8.2% → 6.8% in 4 weeks)
- **Lifestyle Success:** Sustainable weight loss through realistic changes
- **Medication Tolerance:** No side effects from metformin or lisinopril
- **Risk Stratification:** Moderate cardiovascular risk, improving

---

*Record generated for educational and research purposes. All identifying information has been removed or anonymized in accordance with privacy guidelines.*